Newron Pharmaceuticals (SIX: NWRN)

Last close As at 17/07/2024


0.01 (0.12%)

Market capitalisation


Newron Pharmaceuticals is focused on the central nervous system. Xadago for Parkinson’s disease (PD) is sold in Europe, Japan, the United States and other regions. Evenamide, a novel schizophrenia add-on therapy, is involved in a Phase II/III trial programme targeting schizophrenia.

Xadago is marketed as an add-on to levodopa therapy in PD. It is currently sold in Europe, Japan, the United States and other territories. Generic manufacturers have notified the FDA of their intention to file generic Xadago products. Newron is contesting these filings. Xadago is currently patent protected until at least 2027.

Latest Insights

View More



Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh


Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Marco Caremi

    Executive VP of Business Development

  • Stefan Weber


Balance Sheet

Forecast net cash (€m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual (17.0) 14.9 49.3
Relative (19.3) 4.6 32.9
52 week high/low CHF11.0/CHF4.2


Newron is developing evenamide as an add-on therapy for poorly managed and treatment-resistant schizophrenia (TRS). In April/May 2024, Newron shared positive results from a Phase II/III trial (study 008A) in patients with schizophrenia who are taking antipsychotics but not classified as having TRS (primary and key secondary endpoints met). In January 2024, positive final results (12-month data for the full patient cohort) were announced for a Phase II trial (study 014/015) in TRS patients. Over 70% of patients experienced a clinically meaningful reduction in disease severity and 25% achieved remission. With these encouraging results in hand, Newron now intends to begin a potentially pivotal, multinational Phase III schizophrenia programme (expected to start in 2024). In its FY23 results, Newron recorded total revenue of €9.1m (up 48.6% y-o-y) for the period, primarily derived from Xadago-related royalty income.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2022A 6.1 (12.6) (17.0) (95.34) N/A N/A
2023A 9.1 (11.2) (16.0) (89.81) N/A N/A
2024E 24.3 2.1 (2.6) (14.12) N/A N/A
2025E 27.1 3.3 (0.8) (4.31) N/A N/A

Further insights



Newron Pharmaceuticals: EKF 2023 QuickView



Deutsches Eigenkapitalforum (EKF) 2022 healthcare



Deutsches Eigenkapitalforum (EKF) 2022


Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free